Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2003

View Archived Issues

Spotlight on new drugs to treat female sexual dysfunction

Spotlight on "diabesity"

NIAID grant for inhaled biodefense drug development at Coley

TaiGen and TTY Biopharm sign joint development, marketing agreement for DB-67

New inhibitors of FAK and other kinases developed at Aventis Pharma

Aventis claims new protein kinase inhibitors for use in neurological disorders

AstraZeneca describes a novel series of dual CCR3 modulators/H1 antagonists

Schering-Plough claims new NK1 antagonists for emesis, anxiety, depression, etc.

New muscarinic M3 antagonists covered by Boehringer Ingelheim patent

Japanese researchers identify c-fos expression modulators for cancer therapy

GSK scientists present novel antibacterial PDF inhibitors

Long-term evaluation of anastrozole and tamoxifen in postmenopausal women with breast cancer

A novel pneumococcal vaccine reported effective in children with or without HIV

NO-releasing aspirin protects against gastrointestinal damage caused by low-dose aspirin

Eberconazole as an alternative to miconazole in dermatophytosis

Aspreva to develop CellCept for autoimmune diseases

AVP-13358 well tolerated in phase I trial

Baxter completes acquisition of Aralast

Shionogi obtains Japanese distribution rights to moxifloxacin

Rolling NDA submission for clofarabine begins

DOV to purchase Elan's stake in joint venture

Forest proceeds with expanded program of memantine for neuropathic pain

Phase II trial evaluates pixantrone as part of BSHAP regimen for NHL

Approvable letter issued for Foradil Certihaler

Fast track status for T-67 in hepatocellular carcinoma

Potent JAK3 inhibitor shows efficacy in ear edema model

Specific bradycardic agent with oral activity designed by Japanese researchers

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...